Transcriptome of rNLS8 mice and controls injected with non-targeting control ASO
We asked how knockdown of genes associated with neurodegeneration using antisense oligonucleotides (ASO) affects disease phenotypes in an inducible TDP-43 transgenic mouse model (rNLS8, Walker et al., Acta Neuropathologica 2015) backcrossed to the C57BL/6 background. This dataset includes only the non-targeting control, which was also used as a replication cohort for transcriptional changes in rNLS8 mice (Rezaei et al., in revision at Nature Communications). We show cholesterol dysmetabolism and marker genes of disease-associated oligodendrocytes in the brain of rNLS8 mice. Data from mice receiving the targeting ASOs will be made available upon publication of the manuscript (Kocsis-Jutka et al, in preparation). Overall design: 17-19 week old rNLS8 mice and monogenic control littermates were injected intracerebroventricularly with a non-targeting control antisense oligonucleotide (CCTATAGGACTATCCAGGAA). As in Jiang et al. (Neuron 2016), the injection consisted of 350 µg ASO in a total volume of 10 µL. All animals were maintained on a doxycycline diet (200 mg/kg, Ssniff, Germany) until two weeks after injection. The animals were then switched to standard chow without doxycycline to induce the TDP-43?NLS transgene. The animals were sacrificed 3 weeks later. The experiment was done in two independent cohorts (A and B). Data from mice receiving the targeting ASO will be releases once the manuscript is published (Kocsis-Jutka et al, in preparation).